2017 U.S. drug approvals in neurology and psychiatry


The U.S. Food and Drug Administration approved 46 new therapies in 2017, up from only 22 the year before. The following is a list of the new medications for neurology and psychiatry.

  • Safinamide (Xadago, Newron Pharmaceuticals): a monoamine oxidase (MAO)-B inhibitor approved as adjunctive therapy in Parkinson’s disease with motor fluctuations. A phase III trial reported that safinamide 50 or 100 mg/day as an add-on to levodopa-carbidopa significantly increased On time and improved UPDRS Part III motor scores (Borgohain et al. Mov Disord 2014;29:229-237). The FDA rejected the drug in 2014, but approved the resubmission in March 2017.

It takes 30 seconds

Recommend to a Colleague Go back to home page